Get the Stockscreener App
11.52
0.69%
-0.08
After Hours:
11.53
0.010
+0.09%
Abivax Adr stock is traded at $11.52, with a volume of 18,714.
It is down -0.69% in the last 24 hours and down -9.36% over the past month.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.
See More
Previous Close:
$11.60
Open:
$11.54
24h Volume:
18,714
Relative Volume:
0.24
Market Cap:
$728.27M
Revenue:
-
Net Income/Loss:
$-159.39M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-105.22M
1W Performance:
+6.08%
1M Performance:
-9.36%
6M Performance:
-19.44%
1Y Performance:
+0.00%
1-Day Range:
$11.40
$11.68
1-Week Range:
$10.92
$11.84
52-Week Range:
$7.995
$17.02
Abivax Adr Stock (ABVX) Company Profile
Abivax Adr Stock (ABVX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-23 | Initiated | Leerink Partners | Outperform |
| Nov-14-23 | Initiated | Morgan Stanley | Equal-Weight |
Abivax Adr Stock (ABVX) Latest News
Abivax SA Unveils New Ulcerative Colitis Treatment Data - TipRanks
Abivax Reports Progress in Ulcerative Colitis Therapy - TipRanks
DEADLINE ALERT for ABR, FIVE, DXC, and INDV: The Law - GlobeNewswire
Wall Street Analysts Believe Abivax SA Sponsored ADR (ABVX) Could Rally 193.62%: Here's is How to Trade - MSN
Is Abivax SA Sponsored ADR (ABVX) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Wall Street Analysts Believe Abivax SA Sponsored ADR (ABVX) Could Rally 193.62%: Here's is How to Trade - Yahoo Finance
Abivax SA Details Financial Struggles and Advances - TipRanks
Abivax SA Reveals Soaring R&D Costs in H1 2024 - TipRanks
Inflammatory Bowel Disease Treatment Market Size Expected to Reach USD 33.19 Bn by 2032 - GlobeNewswire Inc.
Abivax SA Advances with Positive Trial OutcomesTipRanks.com - TipRanks
Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting - GlobeNewswire Inc.
Abivax SA Announces Upcoming General MeetingTipRanks.com - TipRanks
Guggenheim starts Abivax stock with Buy, cites promising ulcerative colitis drug By Investing.com - Investing.com
Abivax SA Secures Funding and Expands Operations - TipRanks
Citi Appointed as Depositary Bank for Abivax SA's ADR Program - Business Wire
Abivax Adr Stock (ABVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):